Skip to Content
Merck
  • Common ocular effects reported to a poison control center after systemic absorption of drugs in therapeutic and toxic doses.

Common ocular effects reported to a poison control center after systemic absorption of drugs in therapeutic and toxic doses.

Current opinion in ophthalmology (2014-09-17)
Ann Slattery, Erica Liebelt, LaDonna A Gaines
ABSTRACT

Ocular effects resulting from medications assist toxicologists in determining substances involved when treating a poisoned patient. The intention of this review is to discuss the most common ocular effects, the medications that cause them, and the mechanisms by which they occur. According to National Poison Data System, the most common reported ocular effects following a drug ingestion/injection/inhalation are mydriasis, miosis, and nystagmus. The most common drug/drug classes reported to a regional poison control center causing these ocular effects include the following: first, mydriasis - amphetamines and diphenhydramine; second, miosis - clonidine and opioids; third, nystagmus - dextromethorphan. However, many other drugs/substances can cause these effects along with other systemic effects. Ocular findings are a pertinent component of any patient assessment involving therapeutic and/or toxic exposure to medications and other substances.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Dextromethorphan hydrobromide monohydrate, ≥99% (TLC)
Supelco
Dextromethorphan HBr, certified reference material, pharmaceutical secondary standard
USP
Dextromethorphan hydrobromide, United States Pharmacopeia (USP) Reference Standard
Supelco
Clonidine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Dextromethorphan hydrobromide, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Dextromethorphan hydrobromide, meets USP testing specifications